Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests a builder of well being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. Pharmaceutical R amp D focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler pulmonary drugs. Orion s net sales in amounted to EUR million and the company had about , employees. Orion s A and B shares are listed on NASDAQ OMX Helsinki.
Quote | Orion Corp New B Shs (OTCMKTS:ORINF)
Last: | $47.16 |
---|---|
Change Percent: | 0.0% |
Open: | $0 |
Close: | $47.16 |
High: | $0 |
Low: | $0 |
Volume: | 154 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Orion Corp New B Shs (OTCMKTS:ORINF)
2024-03-20 04:08:04 ET More on Orion Oyj Orion Oyj (ORINF) Q4 2023 Earnings Call Transcript Orion collaborates with Glykos to develop next-generation ADCs Historical earnings data for Orion Oyj Dividend scorecard for Orion Oyj Financial information fo...
2024-02-13 13:42:10 ET Orion Oyj (ORINF) Q4 2023 Earnings Call Transcript February 13, 2024 6:30 AM ET Company Participants Tuukka Hirvonen - Investor Relations & Financial Communications Officer Liisa Hurme - President, CEO & Chairman of Executive Management...
Message Board Posts | Orion Corp New B Shs (OTCMKTS:ORINF)
Subject | By | Source | When |
---|---|---|---|
Emylers: ORINF Financials Monday, July 14, 2014 10:32:01 PM Orion Corporation OY Data is unavailable | Emylers | investorshangout | 07/15/2014 2:32:03 AM |
chartguy89: ORINF 25.00 Stock Charts $ORINF 1 Month Chart | chartguy89 | investorshangout | 03/09/2014 6:43:05 AM |
chartguy89: ORINF Stock Charts Last: -2.00 Friday, February 28, 2014 at 1:29:06 PM $ORINF 1 | chartguy89 | investorshangout | 02/28/2014 6:29:17 PM |
News, Short Squeeze, Breakout and More Instantly...
Orion Corp New B Shs Company Name:
ORINF Stock Symbol:
OTCMKTS Market:
ORION CORPORATION PRESS RELEASE 26 JANUARY 2024 at 09.00 EET Additional ODM-208/MK-5684 Phase II data presented at ASCO-GU 2024 Orion presented yesterday at the 2024 ASCO GU Cancers Symposium a poster with additional data from the ongoing Phase II CYPIDES trial evaluating the safety...
ORION CORPORATION PRESS RELEASE 8 JANUARY 2024 at 09.00 EET Orion and Glykos announce research collaboration and licensing agreement to develop next-generation ADCs Orion Corporation and Glykos Finland Oy announced today that they have entered into a research collaborat...
ORION CORPORATION PRESS RELEASE 05 JANUARY 2023 at 13:45 EET Orion and MSD Announce Initiation of Two Phase 3 Trials Evaluating ODM-208/MK5684 in Certain Patients with Metastatic Castration-Resistant Prostate Cancer OMAHA1 and OMAHA2a are the first Phase 3 trials to be initiated for...